Transdermal and topical pharmacotherapy for male sexual dysfunction

Bibliography

• SALASHE SJ, BERNSTEIN G, SENKARIK MS: Surgical anatomy of the skin. McGraw Hill (1988):241.
   Google Scholar
• FREINKEL R, WOODBY D: The Biology of the skin. Parthenon Publishing (2001):162.
   Google Scholar
• BOUWSTRA JA, HONEYWELL-NGUYEN PL: Skin structure and mode of action of vesicles. Adv. Drug Deliv. Rev. (2002) 54\(Suppl. 1):541–555.
   Google Scholar
• MORALES A: Developmental status of topical therapies for erectile and ejaculatory function. Int. J. Imp. Res. (2000) 12\(Suppl. 4):S80–S85.
   PubMedGoogle Scholar
• PRYOR JL, REDMAN B: New therapies and delivery mechanisms for treatment of erectile dysfunction. Int. J. Imp. Res. (2000) 12:S158.
   PubMed Web of Science ®Google Scholar
• NIH Consensus Developmental Panel on Impotence. JAMA (1993) 270: 83.
   PubMedGoogle Scholar
• Gray's Anatomy of the Human Body, 30th edition ed.
   Google Scholar
• ABOSEIF SR, LUE TF: Fundamentals and hemodynamics of penile erection. Cardiovasc. Intervent. Radiol. (1988) 11(4):185–190.
   PubMed Web of Science ®Google Scholar
• RAJFER J, ARONSON WJ, BUSH PA, DOREY FJ, IGNARRO LJ: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to noradrenergic, noncholinergic transmission. N Engl. J. Med. (1992) 326(2):90–94.
   PubMed Web of Science ®Google Scholar
• OWEN JA SAUNDERS F, HARRIS C et al.: Topical nitroglycerin: a potential treatment for impotence. J. Urol. (1989) 141(3):546–548.
   PubMed Web of Science ®Google Scholar
• KIM ED, ELRASHIDY R, MCVARY KT: Papaverine topical gel for treatment of erectile dysfunction. J. Urol. (1995) 153(2):361–365.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN I, PAYTON TR, SCHECHTER PJ: A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the office treatment of erectile dysfunction. Urology (2001) 57(2):301–305.
   PubMed Web of Science ®Google Scholar
• PADMA-NATHAN H, STEIDLE C, SALEM S, TAYSE N, YEAGER J, HARNING R: The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two Phase II studies in mild-to-moderate and severe ED. Int. J. Impot. Res. (2003) 15(1):10–17.
   PubMed Web of Science ®Google Scholar
• HELLSTROM WJ, BIVALACQUA TJ: Peyronie's disease: etiology, medical, and surgical therapy. J. AndroL (2000) 21(3):347–354.
   PubMed Web of Science ®Google Scholar
• ANDERSON MS, SHANKEY TV LUBRANO T, MULHALL JP: In-vitro inhibition of peyronie's plaque fibroblast proliferation by biologic agents. Int. J. Impot. Res. (2000) 12\(Suppl. 3):525–531.
   Google Scholar
• FITCH W, EASTERLING WJ: Topical verapamil, trifluoroperazine, and magnesium sulafate for peyronie's disease. Int. J. Impot. Res. (2001)13:S62.
   Google Scholar
• MARTIN DJ, BADWAN R, PARKER M, MULHALL J: Transdermal application of verapamil gel to penile shaft fails to infiltrate tunica albuginea. J. Urol. (2002) 168(6):2483–2485.
   PubMed Web of Science ®Google Scholar
• RIEDL CR, PLAS E, ENGELHARDT P, DAHA K, PFLUGER H: Iontophoresis for treatment of Peyronie's disease. J. Urol. (2000) 163(1):95–99.
   PubMed Web of Science ®Google Scholar
• MILLS TM, REILLY CM, LEWIS R.W: Androgens and penile erection: a review. J. AndroL (1996) 17(6):633–638.
   PubMed Web of Science ®Google Scholar
• SHABSIGH R: The effects of testosteroneon the cavernous tissue and erectile function. World J. Urol. (1997) 5(1):21–26.
   Google Scholar
• PARK K, KIM SW, KIM KD, PAICK L: Effects of androgens on the expression of nitric oxide synthase in mRNAs in rat orpus cavernosum. BJU Int. (1999) 83(3):327–333.
   PubMed Web of Science ®Google Scholar
• PIERCE JG, PARSONS TF: Glycoprotein hormones structure and function. A. Rev. Biochem. (1981) 50:465–495.
   PubMed Web of Science ®Google Scholar
• WOLLESEN F, SWERDLOFF RS, ODELL WD: LH and FSH responses to luteinizing releasing hormones in normal adult human males. Metabolism (1976) 25(11):1275–1285.
   PubMed Web of Science ®Google Scholar
• LUGG JA, RAJFER J, GONZALEZ-CADAVID NF: Dihydrotestosterone is the active androgen in the maintenance of nitric-oxide mediated penile erection in the rat. Endocrinology (1995) 136(4): 1495–1501.
   PubMed Web of Science ®Google Scholar
• MARIN R, ESCRIG A, ABREU P, MAS M: Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol. Reprod. (1999) 61(4):1012–1016.
   PubMed Web of Science ®Google Scholar
• ZHANG XH, HU LQ, ZHENG XM, LI SW: Apoptosis in rat erectile tissue induced by castration. Asian J. Androl (1999) 1(4):181–185.
   PubMedGoogle Scholar
• DAI YT, STOPPER V, LEWIS R, MILLS T: Effects of castration and testosterone replacement on veno-occlusion during penile erection in the rat. Asian J. AndroL (1999) 1(1-2):53–59.
   PubMedGoogle Scholar
• BANCROFT J: Hormones and human sexual behavior. J. Sex Marital They. (1984) 10(1):3–21.
   PubMed Web of Science ®Google Scholar
• AHMED SR, BOUCHER AE, MANNI k Transdermal testosterone therapy in the treatment of male hypogonadism. j Clin. Endocrinol Metab. (1988) 66(3):546–551.
   Google Scholar
• MCCLURE RD, OSES R, ERNEST ML: Hypogonadal impotence treated by transdermal testosterone. Urology (1991) 37(3):224–228.
   PubMed Web of Science ®Google Scholar
• MEIKLE AW, MAZER NA, MOELLMER JF: Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J. Clin. Endocrinol Metab. (1992) 74(3):623–628.
   PubMed Web of Science ®Google Scholar
• ARVER S, DOBS AS, MEIKLE AE: Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin. Endocrinol (1997) 47(6):727–737.
   Google Scholar
• WANG C, SWEDLOFF R, KIPNESS M et al.: New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmakokinetics study in hypogonadal en. J. Clin. Endocrinol Metab. (2004) 89(8):3821–3829.
   PubMed Web of Science ®Google Scholar
• STEIDLE C, SCHWARTZ S, JACOBY K, SEBREE T, SMITH T, BACHAND R; NORTH AMERICAN AA2500 T GEL STUDY GROUP: AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J. Clin. Endocrinol Metab. (2003) 88(6):2673–2681.
   PubMed Web of Science ®Google Scholar
• KORBONITS M, SLAWIK M, CULLEN D et al.: A comparison of a novel testosterone bioadhesive buccal system, Striant, with a testosterone adhesive patch in hypogonadal males. J. Clin. Endocrinol Metab. (2004) 89(5):2039–2043.
   PubMed Web of Science ®Google Scholar